Cordlife Group Limited · SGX:P8A
Cordlife — FY2022 Earnings Presentation
21 slides from Cordlife's earnings presentation, 2023
Slide 1: FY2022 Results Presentation
FY2022 Results Presentation
Slide 2: Disclaimer
Disclaimer This presentation does not constitute, or form any part of any offer for sale or subscription of, or solicitation of any offer to buy or subscribe for, any securities in Cordlife Group Limited (“Cordlife”) in Singapore or any other jurisdiction nor shall it or any part of it form the basi
Slide 3: Content
Content 1 Results Summary 2 Financial Highlights 3 Outlook & Growth Strategies 3
Slide 4: 2H2022 Results Summary
2H2022 Results Summary REVENUE GROSS PROFIT GP MARGIN S$28.9 million S$19.6 million 67.8% 10.2% increase over 1H2022 11.6% increase over 1H2022 0.8 pp increase over 1H2022 NET PROFIT OPERATING NET PROFIT MARGIN S$3.0 million 6.9% 58.0% increase over 1H2022 0.7 pp decrease over 1H2022 4
Slide 5: FY2022 Results Summary
FY2022 Results Summary REVENUE GROSS PROFIT GP MARGIN S$55.2 million S$37.2 million 67.4% (2.7)% y-o-y (5.8)% y-o-y (2.3) pp y-o-y NET PROFIT OPERATING NET CASH1 NET PROFIT MARGIN S$4.9 million 6.6% S$79.3 million (20.4)% y-o-y +S$4.7m from 31 Dec 2021 (3.2)pp y-o-y 1: Includes cash and cash equival
Slide 6: Financial Highlights
Financial Highlights 6
Slide 7: Financials – Revenue
Financials – Revenue S$ mil 80.0 69.8 59.0 60.0 56.7 55.2 40.0 20.0 — FY2019 FY2020 FY2021 FY2022 – The Group’s FY2022 revenue decreased 2.7% year-on-year to S$55.2 million. – This was mainly due to lower new samples processed and stored in Singapore which was hit by a spike in COVID-19 cases at the
Slide 8: Financials – Diagnostics Revenue
Financials – Diagnostics Revenue S$ mil 5.0 4.0 3.0 2.0 1.0 — FY2019 FY2020 FY2021 FY2022 – The Group’s Diagnostics revenue increased 21.6% year-on-year to S$4.3 million. – The increase was contributed by all markets with 35.2% of the increase contributed by the Philippines market. 8
Slide 9: Diagnostics Revenue by segment
Financials – Diagnostics Revenue by segment S$ mil 5.00 4.00 3.00 2.00 1.00 — FY2019 FY2020 FY2021 FY2022 Children Women 9
Slide 10: Quarter-on-quarter Revenue
Financials – Quarter-on-quarter Revenue S$ mil 20.0 17.7 18.0 17.7 17.5 16.6 16.5 15.0 14.6 14.8 14.6 14.6 14.0 14.4 13.9 13.9 13.4 13.3 13.0 12.5 10.0 7.5 5.0 2.5 — 1Q2019 2Q2019 3Q2019 4Q2019 1Q2020 2Q2020 3Q2020 4Q2020 1Q2021 2Q2021 3Q2021 4Q2021 1Q2022 2Q2022 3Q2022 4Q2022 10
Slide 11: Financials – Gross Profit
Financials – Gross Profit S$ mil 90 68.7% 68.0% 69.7% 67.4% 80 70 60 50 47.9 40.1 39.5 40 37.2 30 20 10 0 FY2019 FY2020 FY2021 FY2022 Gross profit Gross profit Margin 11
Slide 12: Financials – Operating profit after tax
Financials – Operating profit after tax 10 S$ mil 9 10.2% 9.7% 8.4% 6.6% 8 7 5.8 6.0 6 5.5 5 4 3.6 3 2 1 0 FY2019 FY2020 FY2021 FY2022 Operating profit after tax Net operating profit margin 12
Slide 13: Financials – Balance Sheet
Financials – Balance Sheet S$’ mil As at 31 Dec 2022 As at 31 Dec 2021 Net Assets 134.3 136.7 Borrowings — — Gearing1 (%) — — Cash & Cash Equivalents2, Fixed Deposits, Short-term and Long-term 79.3 74.6 Investments Net Asset Value Per Share (SG cents) 52.48 53.54 1: Total Borrowings/Total Equity 2:
Slide 14: Financials – Cash Flow
Financials – Cash Flow For the year ended For the year ended S$’ mil 31 Dec 2022 31 Dec 2021 Net cash generated from operating activities 5.9 9.5 Net cash used in investing activities1 4.2 (23.9) Net cash used in financing activities (11.7) 3.4 Net increase in cash and cash equivalents 13.4 15.5 dur
Slide 15: Outlook & Growth Strategies
Outlook & Growth Strategies 15
Slide 16: Outlook
Outlook Business Outlook – The Group managed to achieve stability in revenue over the past quarters by adapting quickly and pivoting with the evolving landscape, with the diagnostics services continuing on a positive growth trajectory. – The prolonged pandemic induced challenges, rising inflation in
Slide 17: Growth Strategies
Growth Strategies Increase penetration jor market share Increase product scope Organic Open new markets Growth Facilitate development of stem cell Create new engines of growth ic with current Mergers& Acquisitions Eamings accretive Targeting Asia
Slide 18: Banking Services
Banking Services Gut Microbiome Banking Lenticule 2022 Banking Singapore 2021 Singapore, Hong Kong Cord Tissue Banking 2020 Cord Tissue 2016 Mesenchymal Singapore, Hong Kong, Indonesia, Philippines, Stem Cell banking India, Myanmar, Malaysia, Macau, Brunei Philippines, Thailand Peripheral Blood 2013
Slide 19: Cord tissue - Increase in clinical trials
Cord tissue - Increase in clinical trials • Graph A: Line plot of yearly registered mesenchymal stem cells-based clinical trials at ClinicalTrials.gov since the first use in 1995 up to 2020. • Graph B: Pie chart of number of clinical trials based on main sources used as highlighted in the legend. •
Slide 20: Cord blood and cord tissue - Increase in clinical trials
Cord blood and cord tissue - Increase in clinical trials BM : Bone Marrow UC : Umbilical Cord Source : https://parentsguidecordblood.org/en/news/2022-update-how-many-clinical-trials-use-cord-blood-or-cord-tissue ; https://doi.org/10.1002/sctm.19-0202 20
Slide 21: Thank you
Thank you 21